GlassScriptPhysician profile
Suvarna Nomula
NPI 1801972070
$5,808.20
in general payments reported to CMS, 2019-2025
21 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $948 · 2021: $645 · 2022: $796 · 2023: $882 · 2024: $564 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,943.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,073.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $822.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $272.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $207.64 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.28 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $172.34 | 2019-2021 | |
| Pfizer INC. | $170.47 | 2019-2025 | |
| Amgen INC. | $139.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $130.99 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $111.86 | 2022 | |
| Abbvie INC. | $111.29 | 2020-2023 | |
| Exact Sciences Corporation | $85.74 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $70.55 | 2019 | |
| Glaxosmithkline, LLC. | $67.61 | 2024-2025 | Trelegy Ellipta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $66.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.36 | 2022-2023 | |
| Abbott Laboratories | $37.45 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Corcept Therapeutics | $24.91 | 2025 | Korlym |
| Allergan, INC. | $24.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suvarna Nomula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.